Chairman of the Board
Former EVP, Legal and Corporate Development, Genzyme
Chairman of the Board
Former EVP, Legal and Corporate Development, Genzyme
Peter Wirth is an industry veteran with a track record of value creation in biotechnology. Mr. Wirth was a senior executive at Genzyme from 1996 until its acquisition by Sanofi in 2011, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary. During his time at Genzyme, Mr. Wirth had senior management responsibility for the company’s legal function, corporate development function, molecular oncology division, polymer drug discovery and development division and enterprise risk management function. He was instrumental in helping build Genzyme from a small start-up to a diversified, multi-billion dollar enterprise with more than 12,000 employees in locations spanning the globe. Prior to Genzyme, Mr. Wirth practiced law at Palmer & Dodge LLP, where he was head of the firm’s biotechnology practice group and served as outside counsel for Genzyme as well as numerous other biopharmaceutical companies. He is currently Chairman of FORMA Therapeutics, a small molecule drug discovery company, Executive Chairman of ZappRx, a digital health company, and Senior Advisor to Zai Lab Limited, a Shanghai-based biopharmaceutical company. Mr. Wirth was a 2012 Advanced Leadership Fellow at Harvard University. He received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School.
Founder and Managing General Partner at Samsara BioCapitalView Bio
Founder and Managing General Partner at Samsara BioCapital
Srinivas Akkaraju, M.D., Ph.D., has nearly 20 years of investment and operational experience in the life sciences sector. Dr. Akkaraju is a Founder and Managing General Partner at Samsara BioCapital. Prior to founding Samsara BioCapital, he served as a General Partner of Sofinnova Ventures from April 2013 to June 2016, Managing Director of New Leaf Venture Partners from January 2009 to April 2013, and Managing Director of Panorama Capital, a private equity firm that he helped found, from September 2006 to December 2008. Before co-founding Panorama Capital, he was a Partner at J.P. Morgan Partners, and earlier in his career, he was in Business and Corporate Development at Genentech (now a wholly owned member of The Roche Group). Dr. Akkaraju currently serves as chairman of the board of Versartis and as a director of Intercept Pharmaceuticals, Seattle Genetics and aTyr Pharma. Previously, he served on the boards of Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp. and Amarin Corp. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University.
Executive Chairman, Kaleido BiosciencesView Bio
Executive Chairman, Kaleido Biosciences
Mr. Bonney is currently executive chairman of Kaleido Biosciences, a privately held, clinical-stage biotechnology company. A veteran of the biopharmaceutical industry, he initially served as Kaleido’s CEO until August 2018. Previously, Mr. Bonney was chief executive officer and director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew into a leading antibiotic company and was acquired by Merck in early 2015 for $9.5 billion. Prior to Cubist, Mr. Bonney was vice president of sales and marketing at Biogen, where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating and strategic roles, including National Business Director.
Mr. Bonney chairs the boards of Alnylam Pharmaceuticals and Magenta Therapeutics and serves on the boards of Celgene Corporation and Sarepta Therapeutics. He is chair of the board of trustees of Bates College and a member of the board of the Whitehead Institute for Biomedical Research. Mr. Bonney was a regional winner and national finalist in 2013 in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year in 2011. He received his undergraduate degree in Economics from Bates College.
Former Chief Financial Officer, Millennium PharmaceuticalsView Bio
Former Chief Financial Officer, Millennium Pharmaceuticals
Marsha H. Fanucci is has served in a number of executive leadership positions at Millennium Pharmaceuticals from 2000 to 2009, including Chief Financial Officer and Senior Vice President of Strategy, Vice President of Finance and Strategy, and Vice President of Corporate Development and Strategy. During her tenure, Ms. Fanucci directly contributed to a series of strategic processes, advanced Millennium to profitability and was instrumental in the acquisition by Takeda Pharmaceutical Company in 2008 for $8.8 billion. Previously, Ms. Fanucci was Vice President of Corporate Development and Strategy at Genzyme Corp. and Vice President and Director at Arthur D. Little. Ms. Fanucci serves on the boards of directors of several biotech companies, including Alnylam Pharmaceuticals, FORMA Therapeutics, Ironwood Pharmaceuticals and Momenta Pharmaceuticals, and non- profit organization The Schwartz Center for Compassionate Care. Ms. Fanucci received a B.S. in pharmacy from West Virginia University Medical School and an M.B.A. from Northeastern University.
Managing Partner, Polaris Venture PartnersView Bio
Managing Partner, Polaris Venture Partners
Amir Nashat, Ph.D., is a managing partner at Polaris Venture Partners, where he has worked since 2002, and focuses on investments in the life sciences. Dr. Nashat serves on the boards of directors of AgBiome, aTyr Pharmaceuticals, BIND Therapeutics, Fate Therapeutics, Promedior Pharmaceuticals, Scholar Rock and Selecta Biosciences. Dr. Nashat also serves on the board of the Partners Innovation Fund and is a mentor with the Deshpande Center for Technological Innovation at the Massachusetts Institute of Technology (MIT). He has been named to the Forbes Midas list of Top 100 Venture Capitalists. Prior to joining Polaris, Dr. Nashat completed his Ph.D. as a Hertz Fellow in Chemical Engineering at MIT with a minor in Biology under the guidance of Dr. Robert Langer. He earned his M.S. and B.S. in materials science and mechanical engineering from the University of California, Berkeley.
Retired Professor, Harvard Business SchoolView Bio
Retired Professor, Harvard Business School
Dr. Sato retired recently as Professor of Management Practice at Harvard Business School, where she taught from 2006-2017. During this time, she also had an appointment as Professor of the Practice in the Department of Molecular and Cell Biology at Harvard University. Before returning to academia, Dr. Sato spent close to 14 years at Vertex Pharmaceuticals, joining in 1992 as Chief Scientific Officer and becoming President in 2000 with general management responsibility for business and corporate development, commercial operations, legal, finance, and research and development. Before joining Vertex, Dr. Sato was vice president of research at Biogen, where she led research programs in the areas of inflammation, thrombosis, and HIV disease, and was a member of the executive management team of the company.
Currently, Dr. Sato is chair of the boards of Denali and Vir Biotechnology. She serves on the boards of Bristol Myers Squibb Company and Borg Warner Corporation, and is also a member of the board of Overseers of the Isabella Stewart Gardner Museum. Dr. Sato received her A.B. from Radcliffe College, and her A.M. and Ph.D. degrees from Harvard University. She conducted her postdoctoral work at the University of California Berkeley and Stanford Medical Center.
Institute Professor, Massachusetts Institute of TechnologyView Bio
Institute Professor, Massachusetts Institute of Technology
Phillip Sharp, Ph.D., a world leader of research in molecular biology and biochemistry, is Institute Professor at the Massachusetts Institute of Technology. Much of Dr. Sharp's scientific work has been conducted at MIT's Center for Cancer Research (now the Koch Institute), which he joined in 1974 and directed from 1985 to 1991. He subsequently led the Department of Biology from 1991 to 1999 before assuming the directorship of the McGovern Institute from 2000-2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark achievement was the discovery of RNA splicing in 1977. His discovery fundamentally changed scientists' understanding of the structure of genes and earned Dr. Sharp the 1993 Nobel Prize in Physiology and Medicine. His lab has now turned its attention to understanding how RNA molecules act as switched to turn genes on and off (RNA interference). Dr. Sharp has authored over 385 scientific papers and has received numerous awards and honorary degrees. He earned his B.A. from Union College, KY in 1966 and a Ph.D. in chemistry from the University of Illinois, Champaign-Urbana in 1969. His did his postdoctoral training at the California Institute of Technology, where he studied the molecular biology of plasmids from bacteria.
Director of the Center for Thoracic Cancers at Massachusetts General HospitalView Bio
Director of the Center for Thoracic Cancers at Massachusetts General Hospital
Alice Tsang Shaw, M.D., Ph.D., is a highly respected oncologist and recognized leader in translational medicine and the development of targeted cancer therapies. She is the Director of the Center for Thoracic Cancers, the Paula O'Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital (MGH), Co-leader of the Dana-Farber/MGH/Harvard Center Thoracic Oncology Program, and Professor of Medicine at Harvard Medical School. She is also the Co-leader of the Stand Up To Cancer (SU2C) Lung Cancer Dream Team. In addition to caring for patients, Dr. Shaw performs clinical and translational research with a focus on developing targeted treatments for oncogene-driven lung cancers and elucidating resistance mechanisms to targeted therapies. Her research has contributed to the development of numerous approved targeted therapies, including crizotinib (Xalkori), ceritinib (Zykadia), alectinib (Alecensa), and lorlatinib (Lorbrena). One of her current areas of focus is on developing combination therapy strategies aimed at overcoming drug resistance. Dr. Shaw is a standing member of the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee. She has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the V Foundation for Cancer Research, Uniting Against Lung Cancer, the National Foundation for Cancer Research, and the National Institutes of Health/National Cancer Institute. She received her B.A. in biochemistry from Harvard University and her M.D. and Ph.D. from Harvard Medical School. She completed her residency at MGH, oncology fellowship at Dana-Farber/MGH and her postdoctoral work at Massachusetts Institute of Technology.
President, Chief Executive Officer, SyrosView Bio
President, Chief Executive Officer, Syros
Nancy has an established track record of value creation in biotechnology. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals and, previously, Vice President of Clinical Development at Biogen. Nancy has overseen the development of the numerous medicines including AVONEX, TYSABRI, VELCADE, ENTYVIO as well as multiple drugs currently in development in oncology. Under Nancy's leadership at Millennium, VELCADE became a mainstay of treatment for multiple myeloma and a billion-dollar commercial blockbuster. Nancy also built and advanced Millennium's promising pipeline of clinical-stage investigational medicines for cancer and inflammatory diseases. Nancy started her career as a member of the faculty at Harvard Medical School and neurology staff at Massachusetts General Hospital (MGH). She trained in neurology and internal medicine at the MGH and graduated with a bachelor's degree in biology from Princeton. She is currently a member of the board of directors of Seattle Genetics.
Member, Whitehead InstituteView Bio
Member, Whitehead Institute
Richard A. Young, Ph.D., is a member of the Whitehead Institute and professor of Biology at the Massachusetts Institute of Technology. In May 2012, he was elected into the National Academy of Sciences. Dr. Young’s research focuses on the regulatory circuitry that controls the gene expressions programs in each cell, including mapping the regulatory circuitry that controls cell state and differentiation in mice and humans. Experimental and computational technologies are used to determine how signaling pathways, transcription factors, chromatin regulators and small RNAs control gene expression programs in embryonic stem cells. Dr. Young has served as an advisor to Science magazine and the World Health Organization. In 2006, Dr. Young was recognized as one of the top 50 leaders in science, technology and business by Scientific American. His awards include a Burroughs Wellcome Scholarships, the Chiron Corporation Biotechnology Research Awards, and Yale’s Wilbur Cross Medal. Dr. Young received his Ph.D. from Yale University.